Genome sequencing of Ewing sarcoma patients reveals genetic predisposition

Posted: Feb 23, 2017

The largest and most comprehensive genomic analysis of individuals with Ewing sarcoma performed to date reveals that some patients are genetically predisposed to developing the cancer.  Learn more...

Genome sequencing of Ewing sarcoma patients reveals genetic predisposition

Low-grade prostate tumors can harbor signs of aggressive cancer

Posted: Feb 14, 2017

In a new study, Center for Cancer Research investigators found that low-grade and high-grade regions of prostate tumor tissue shared mutations typically linked to aggressive cancer. Testing for mutations to specific genes could help clinicians decide whether a patient with an initial low-grade result should undergo a follow-up biopsy. Learn more...

Low-grade prostate tumors can harbor signs of aggressive cancer

Novel target for high-risk neuroblastoma identified in pre-clinical research

Posted: Jan 9, 2017

Pre-clinical research by investigators at the Center for Cancer Research and their colleagues have identified a number of novel epigenetic targets for high-risk neuroblastoma and validated a promising new targeted inhibitor in pre-clinical models.  Read more...

Novel target for high-risk neuroblastoma identified in pre-clinical research

Molecules discovered that block cancer-associated microRNAs

Posted: Dec 29, 2016

Investigators from the Center for Cancer Research have identified a new class of compounds that block the action of a microRNA associated with the development of human cancers, cardiovascular diseases and immune disorders.  Read more...

Molecules discovered that block cancer-associated microRNAs
NF1 protein structure

Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors

Posted: Dec 28, 2016

Brigitte Widemann, Chief of the Pediatric Oncology Branch, led an early-phase clinical trial testing the oral drug selumetinib on children with neurofibromatosis 1 (NF1) and plexiform neurofibromas. The trial results, published in the New England Journal of Medicine on Dec. 28, 2016, showed participants of this trial tolerated the drug and most responded with tumor shrinkage. “Some may say that a 20 percent volume reduction is too small to be meaningful, but to me, just stopping the growth of these devastating tumors is an important achievement,” Widemann says. “The difference we see in these patients is truly unprecedented.” Read more...

Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors

Potential treatment for radiation-induced lung injury identified

Posted: Dec 22, 2016

Researchers from the Center for Cancer Research’s Radiation Oncology Branch have identified a therapeutic target for the possible treatment of lung injury from radiation therapy. Read more...

Potential treatment for radiation-induced lung injury identified
A normal cell, and a cell in which contacts between centromeres and the LINC complex have been abolished.

A crucial step in cell division identified

Posted: Dec 20, 2016

When cell division doesn’t go according to plan, the resulting daughter cells can become unstable or even cancerous. A team of CCR investigators has now discovered a crucial step required for normal cell division to occur. Read more...

A crucial step in cell division identified

Chemotherapy drug shuts down cell growth by triggering a natural checkpoint

Posted: Dec 15, 2016

In a new study published November 23, 2016, in Molecular Cell, researchers in the CCR’s Laboratory of Cell and Developmental Signaling reported the discovery of a previously unknown route for blocking cell growth that can be activated by certain chemotherapy drugs to fight cancer. Read more...

Chemotherapy drug shuts down cell growth by triggering a natural checkpoint

Cellular immunotherapy targets a common human cancer mutation

Posted: Dec 8, 2016

A team of researchers led by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, studied the use of immunotherapy for colorectal cancer. The team identified a method to target the cancer-causing protein produced by a mutant form of the KRAS gene. The patients who participated in the study experienced tumor regression after receiving this targeted immunotherapy approach. The New England Journal of Medicine published the study results on Dec. 8, 2016. Read more...

Cellular immunotherapy targets a common human cancer mutation

Structural biologists capture detailed image of gene regulator’s fleeting form

Posted: Nov 14, 2016

Using an ultrafast, high-intensity radiation source called an X-ray free-electron laser (XFEL), scientists have captured an atomic-level picture of an RNA structure called a riboswitch as it reorganizes itself to regulate protein production. The structure they visualized has never before been seen, and likely exists for only milliseconds after the riboswitch first encounters its activating molecule.  Read more...

 

Structural biologists capture detailed image of gene regulator’s fleeting form

Pages